Jeevan Scientific Technology Limited recently announced the successful completion of a Remote Interactive Evaluation (RIE) conducted by the United States Food and Drug Administration (US FDA). The evaluation, which took place from October 17, 2025 to November 6, 2025, focused on the company's Clinical Pharmacology facility.

Evaluation Scope and Outcome

The US FDA's evaluation encompassed several key areas:

• BA/BE studies
• Operations
• Systems
• Procedures

Notably, the RIE concluded with no critical observations, marking a significant achievement for Jeevan Scientific Technology.

Implications for the Company

The successful completion of this evaluation without any critical observations is a positive development for Jeevan Scientific Technology. It demonstrates the company's commitment to maintaining high standards in its clinical pharmacology operations and adherence to regulatory requirements.

This outcome may potentially:

• Enhance the company's credibility in the pharmaceutical research sector
• Strengthen its position for future collaborations or contracts
• Provide reassurance to stakeholders about the quality of the company's operations

It's important to note that this evaluation is a routine part of regulatory oversight in the pharmaceutical industry. The company will likely continue to be subject to periodic evaluations to ensure ongoing compliance with FDA standards.

Stakeholders may view this development as part of Jeevan Scientific Technology's ongoing efforts to maintain regulatory compliance and operational excellence in its field of clinical pharmacology research.

Jeevan Scientific Technology Limited has successfully completed its Rs 30.74 crore capital raising plan through the allotment of convertible warrants and equity shares. The company's board meeting held on January 2, 2026, approved the allotment of securities to promoters and non-promoters following BSE's in-principle approval.

Major Stake Acquisition by Padmaja Private Trust

In a significant development, Padmaja Private Trust has acquired a substantial 7.53% stake in the company through the recent preferential allotment. The acquisition details are as follows:

This acquisition triggered disclosure requirements under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as Padmaja Private Trust crossed the substantial acquisition threshold.

SEBI Regulatory Compliance

Following the acquisition, Padmaja Private Trust has filed the mandatory disclosure under Regulation 29(1) of SEBI regulations on January 5, 2026. The filing confirms the acquisition details and provides comprehensive information about the trust's holdings:

Complete Allotment Details

The board has successfully allotted the planned securities as outlined in their earlier proposal:

The allotment was completed pursuant to BSE's in-principle approval granted through Letter Reference No. LOD/PREF/HC/FIP/1377/2025-26 dated December 18, 2025.

Updated Capital Structure

Following the allotment, the company's equity capital structure has been revised:

Fund Utilization and Strategic Plans

The funds raised will be utilized for:

This successful capital raise and the entry of Padmaja Private Trust as a substantial investor strengthens Jeevan Scientific Technology's financial position and provides the necessary resources for its planned expansion in the healthcare sector, including potential acquisitions and capacity enhancement initiatives.